Treatment of Spontaneous Bacterial Peritonitis
For community-acquired SBP, immediately initiate IV third-generation cephalosporin (such as cefotaxime) combined with IV albumin (1.5 g/kg on day 1 and 1 g/kg on day 3); for nosocomial or healthcare-associated SBP, start broad-spectrum antibiotics such as meropenem plus daptomycin instead of cephalosporins. 1
Initial Antibiotic Selection
The choice of empirical antibiotics depends critically on where the infection was acquired:
Community-Acquired SBP
- IV third-generation cephalosporin is first-line therapy 1
- This remains effective for most community-acquired cases despite emerging resistance patterns
- Treatment duration: 5-7 days 1
Nosocomial or Healthcare-Associated SBP
- Broad-spectrum antibiotics are mandatory as first-line therapy 1
- Meropenem plus daptomycin is significantly more effective than ceftazidime (86.7% vs 25% resolution rate) 2
- Consider piperacillin-tazobactam or carbapenems based on local susceptibility 3
- This distinction is critical because nosocomial infections have high rates of multidrug-resistant organisms and gram-positive bacteria 4
Additional High-Risk Scenarios Requiring Broad-Spectrum Coverage
- Recent exposure to broad-spectrum antibiotics 1
- Admission with sepsis or septic shock 1
- Patients on quinolone prophylaxis 4
Albumin Administration: Essential Adjunctive Therapy
All patients with SBP should receive IV albumin in addition to antibiotics 1:
- Day 1: 1.5 g/kg body weight (within 6 hours of diagnosis)
- Day 3: 1 g/kg body weight
Who Benefits Most from Albumin?
Patients with the following characteristics derive greatest benefit 1:
- Renal dysfunction (BUN >30 mg/dL or creatinine >1.0 mg/dL)
- Severe hepatic decompensation (bilirubin >5 mg/dL)
- Albumin prevents progression to acute kidney injury and significantly reduces mortality 5
Monitoring Treatment Response
Perform repeat paracentesis 48 hours after initiating antibiotics 1:
- Treatment failure is defined as <25% decrease in PMN count from baseline
- If treatment fails: broaden antibiotic spectrum and investigate secondary peritonitis with abdominal imaging 1
- Repeat paracentesis may be unnecessary if an organism is isolated, susceptible to the antibiotic used, and the patient is clinically improving 1
Common Pitfall
Given increasing antibiotic failure rates that lead to increased mortality, the 48-hour paracentesis is now recommended rather than optional 1. This represents a shift toward more aggressive monitoring.
Important Management Considerations
Non-Selective Beta-Blockers (NSBBs)
- Temporarily hold NSBBs in patients with SBP who develop:
Bacterascites (PMN <250/mm³ with positive culture)
- Do not treat with antibiotics if no signs of infection 1
- Most cases self-resolve or represent contamination
- Perform repeat paracentesis to monitor for progression to SBP 1
Changing Bacterial Epidemiology
The microbiology of SBP has shifted significantly:
- Gram-positive cocci (Staphylococcus, Enterococcus) are increasingly common 4
- Multidrug-resistant organisms are emerging, particularly in nosocomial settings 2, 4
- This explains why traditional third-generation cephalosporins fail more frequently in healthcare-associated infections 2
Key Predictors of Poor Outcome
Independent predictors of 90-day mortality include 2:
- Ineffective response to first-line antibiotic treatment
- Development of acute kidney injury during hospitalization
- Lower baseline mean arterial pressure
This underscores why choosing the correct initial antibiotic regimen based on acquisition setting is critical—you may not get a second chance.